RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

ChemoCentryx Liabilities 2024

ChemoCentryx Liabilities

139.53 M USD

ChemoCentryx Dividend yield

Ticker

CCXI

ISIN

US16383L1061

WKN

A0NBM2

In 2024, ChemoCentryx's total liabilities amounted to 139.53 M USD, a 0% difference from the 0 USD total liabilities in the previous year.

ChemoCentryx Aktienanalyse

What does ChemoCentryx do?

ChemoCentryx Inc. was founded in 1997 and is based in Mountain View, California. The company specializes in the development of medications for rare autoimmune diseases, cancer, and inflammation. Since its founding, ChemoCentryx Inc. has developed a variety of drug candidates, some of which are in clinical phases or as finished products. The business model of ChemoCentryx Inc. is based on the discovery and development of medications targeting chemokines and chemokine receptors. This technology allows for the regulation and control of inflammatory processes. The company also utilizes its proprietary Janus kinase inhibitors (JAK inhibitors) for the treatment of inflammatory diseases. ChemoCentryx Inc. has several business areas. The primary area is the research and development of medications that can be used as candidates against inflammatory, cancer, autoimmune, and fibrosis diseases. The second significant area is collaboration with international partners in the research and development of these medications. The company has also developed specialized tools and technologies to optimize its drug development processes. These techniques include high-throughput screening and X-ray crystallography technologies, as well as biomarker-based diagnostics. One important product of ChemoCentryx Inc. is Avacopan, an oral medication used in the treatment of ANCA-associated vasculitic diseases such as granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Avacopan is a selective antagonist of the C5a receptor, which plays a central role in the inflammatory response. Clinical studies on the efficacy and safety of Avacopan have yielded promising results, and the medication has received Breakthrough Therapy Designation status from the US FDA. Additionally, ChemoCentryx Inc. has successfully identified candidates for the treatment of atopic dermatitis, lupus nephritis, and Crohn's disease. These products are still in the clinical development phase and have great potential to significantly improve the lives of patients suffering from these conditions. Overall, ChemoCentryx Inc. has made significant progress in the discovery and development of drugs that can combat inflammation and other chronic diseases. The company is well-positioned to expand its pipeline and bring additional breakthrough products to market that will play a crucial role in treating diseases that have been difficult to treat in the past. ChemoCentryx ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing ChemoCentryx's Liabilities

ChemoCentryx's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating ChemoCentryx's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing ChemoCentryx's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

ChemoCentryx's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in ChemoCentryx’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about ChemoCentryx Stock

What is the level of liabilities of ChemoCentryx this year?

ChemoCentryx has a debt balance of 139.53 M USD this year.

What were the liabilities of ChemoCentryx compared to the previous year?

The liabilities of ChemoCentryx have increased by 0% dropped compared to the previous year.

What are the consequences of high debt for investors of ChemoCentryx?

High liabilities can pose a risk for investors of ChemoCentryx, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in ChemoCentryx?

Low liabilities mean that ChemoCentryx has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of ChemoCentryx affect the company?

An increase in liabilities of ChemoCentryx can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of ChemoCentryx affect the company?

A decrease in the liabilities of ChemoCentryx can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of ChemoCentryx?

Some factors that can influence the liabilities of ChemoCentryx include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of ChemoCentryx so important for investors?

The liabilities of ChemoCentryx are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can ChemoCentryx take to modify the liabilities?

To change its liabilities, ChemoCentryx can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does ChemoCentryx pay?

Over the past 12 months, ChemoCentryx paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ChemoCentryx is expected to pay a dividend of 0 USD.

What is the dividend yield of ChemoCentryx?

The current dividend yield of ChemoCentryx is .

When does ChemoCentryx pay dividends?

ChemoCentryx pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ChemoCentryx?

ChemoCentryx paid dividends every year for the past 0 years.

What is the dividend of ChemoCentryx?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ChemoCentryx located?

ChemoCentryx is assigned to the 'Health' sector.

Wann musste ich die Aktien von ChemoCentryx kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ChemoCentryx from 6/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/1/2024.

When did ChemoCentryx pay the last dividend?

The last dividend was paid out on 6/1/2024.

What was the dividend of ChemoCentryx in the year 2023?

In the year 2023, ChemoCentryx distributed 0 USD as dividends.

In which currency does ChemoCentryx pay out the dividend?

The dividends of ChemoCentryx are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The ChemoCentryx stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von ChemoCentryx

Our stock analysis for ChemoCentryx Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ChemoCentryx Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.